Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cephalexin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | ESR1 | P03372 | 1/20 | 0.85 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.85 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cephalexin Anhydrous SCHEMBL12961263 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL8467348 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL6663551 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL11569012 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL11985597 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL6663545 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL10925361 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL8481524 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL20703090 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL2961 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951119-B2 | Combination comprising zidovudine and an antimicrobial compound | HELPERBY THERAPEUTICS LIMITED (GB) | 2024-04-09 | — | — | US | disclosed |
| EP-3787622-B1 | COMBINATION COMPRISING ZIDOVUDINE AND AN ANTIMICROBIAL COMPOUND | HELPERBY THERAPEUTICS LTD (GB) | 2023-12-13 | — | — | EP | disclosed |
| US-20220117991-A1 | COMBINATION COMPRISING ZIDOVUDINE AND AN ANTIMICROBIAL COMPOUND | HELPERBY THERAPEUTICS LIMITED (GB) | 2022-04-21 | — | — | US | disclosed |
| EP-3787622-A1 | COMBINATION COMPRISING ZIDOVUDINE AND AN ANTIMICROBIAL COMPOUND | Helperby Therapeutics Limited (GB) | 2021-03-10 | — | — | EP | disclosed |
| CN-112218633-A | Combinations comprising zidovudine and antimicrobial compounds | 赫尔普百治疗有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-7666398-B2 | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666398-B2 | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-02-23 | — | — | US | disclosed |
| CN-1095846-C | Production process of cephem compound | EISAI KAGAKU KK (JP) | 2002-12-11 | — | — | CN | disclosed |
| CN-1184814-A | Production process of cephem compound | EISAI KAGAKU KK (JP) | 1998-06-17 | — | — | CN | disclosed |
| CN-1017335-B | PROCESS FOR PREPARING BETA-LACTAM ANTIBIOTICS | BAYER AG (DE) | 1992-07-08 | — | — | CN | disclosed |
| CN-1035511-A | β-Nei Xiananleikangshengsu its preparation method and as medicine and the application in medicine | BAYER AG (DE) | 1989-09-13 | — | — | CN | disclosed |
| CN-86101382-A | Prepare the method for β-Nei Xiananleikangshengsu and the application in medicine thereof | — | 1986-09-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117991-A1 | COMBINATION COMPRISING ZIDOVUDINE AND AN ANTIMICROBIAL COMPOUND | TPMT, TYMS, SAMHD1 | HSD17B10 1960/4885MAPT 3237/4885ALDH1A1 3697/4885 |
| US-11951119-B2 | Combination comprising zidovudine and an antimicrobial compound | TPMT, TYMS, SAMHD1 | HSD17B10 1960/4885MAPT 3237/4885ALDH1A1 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.